Paps smear

Reading File
Finding Sources
Finding Sources
Searching Images

Pap smear cervical cytology normal abnormal cells

This is a cytology preparation of a cervical sample processed as a ThinPrep Pap smear and imaged by brightfield light microscopy. The right-hand field shows epithelial squamous cells with HPV cytopathic effect (koilocytosis): enlarged, irregular, hyperchromatic nuclei with coarse chromatin, a distinct perinuclear halo, and cytoplasmic clearing; accompanying cytoplasm is often dense and well delineated. The left-hand field displays morphologically normal squamous epithelial cells with uniform nuclei and minimal cytoplasmic clearing, serving as a normal comparator. The sample originates from the cervical transformation zone, where squamous metaplasia occurs; the specimen includes groups of discohesive and cohesive cells arranged in sheets and clusters. Pap staining yields a bluish to green-blue cytoplasm and prominent nuclear detail, enabling assessment of nuclear size, contour, and chromatin pattern. In HPV infection, koilocytosis reflects viral cytopathic effect and is considered a surrogate marker for oncogenic HPV infection; its presence warrants clinical follow-up with HPV typing and cytologic/beyond screening assessment. Clinically, the image is relevant for education, illustrating hallmark cytologic changes used in screening programs, differential diagnoses for squamous cell atypia, and potential progression to cervical intraepithelial neoplasia (CIN). This dual-field photograph aids learners in recognizing contrast between infected and normal epithelium, cytoplasmic maturation, and nuclear irregularity in a single view.

This is a cytology preparation of a cervical sample processed as a ThinPrep Pap smear and imaged by brightfield light microscopy. The right-hand field shows epithelial squamous cells with HPV cytopathic effect (koilocytosis): enlarged, irregular, hyperchromatic nuclei with coarse chromatin, a distinct perinuclear halo, and cytoplasmic clearing; accompanying cytoplasm is often dense and well delineated. The left-hand field displays morphologically normal squamous epithelial cells with uniform nuclei and minimal cytoplasmic clearing, serving as a normal comparator. The sample originates from the cervical transformation zone, where squamous metaplasia occurs; the specimen includes groups of discohesive and cohesive cells arranged in sheets and clusters. Pap staining yields a bluish to green-blue cytoplasm and prominent nuclear detail, enabling assessment of nuclear size, contour, and chromatin pattern. In HPV infection, koilocytosis reflects viral cytopathic effect and is considered a surrogate marker for oncogenic HPV infection; its presence warrants clinical follow-up with HPV typing and cytologic/beyond screening assessment. Clinically, the image is relevant for education, illustrating hallmark cytologic changes used in screening programs, differential diagnoses for squamous cell atypia, and potential progression to cervical intraepithelial neoplasia (CIN). This dual-field photograph aids learners in recognizing contrast between infected and normal epithelium, cytoplasmic maturation, and nuclear irregularity in a single view.

Conventional cervical cytology Pap smear demonstrates opportunistic yeast colonization consistent with Candida species. The primary cellular component comprises intermediate and superficial squamous cells within clusters, with abundant oval budding yeast forms measuring approximately 1–2 μm. Prominent pseudohyphae extend from yeast structures and appear eosinophilic with uneven staining on the cytology smear. A robust neutrophilic inflammatory background accompanies the fungal elements, reflecting active fungal infection and acute inflammatory response. The yeast forms are small, round to ovoid, with smooth contours and budding patterns; the accompanying pseudohyphae appear as elongated filamentous structures, often terminating in small buds. The appearance is diagnostic of Candida infection in vaginal/cervical cytology and can be seen in vulvovaginal candidiasis, cervicitis, or secondary colonization in patients with recent antibiotic exposure or immunocompromise. Consider differential diagnoses that can mimic yeast elements on Pap stain include other yeasts such as Saccharomyces and nonpathogenic contaminants, but the presence of true pseudohyphae and budding yeast strongly favors Candida. Clinically, these findings should prompt correlation with symptoms such as pruritus, discharge, and risk factors like diabetes mellitus, pregnancy, or immune suppression, and guide antifungal therapy decisions. Follow-up cytology or microbiology cultures may be used to determine species.

Conventional cervical cytology Pap smear demonstrates opportunistic yeast colonization consistent with Candida species. The primary cellular component comprises intermediate and superficial squamous cells within clusters, with abundant oval budding yeast forms measuring approximately 1–2 μm. Prominent pseudohyphae extend from yeast structures and appear eosinophilic with uneven staining on the cytology smear. A robust neutrophilic inflammatory background accompanies the fungal elements, reflecting active fungal infection and acute inflammatory response. The yeast forms are small, round to ovoid, with smooth contours and budding patterns; the accompanying pseudohyphae appear as elongated filamentous structures, often terminating in small buds. The appearance is diagnostic of Candida infection in vaginal/cervical cytology and can be seen in vulvovaginal candidiasis, cervicitis, or secondary colonization in patients with recent antibiotic exposure or immunocompromise. Consider differential diagnoses that can mimic yeast elements on Pap stain include other yeasts such as Saccharomyces and nonpathogenic contaminants, but the presence of true pseudohyphae and budding yeast strongly favors Candida. Clinically, these findings should prompt correlation with symptoms such as pruritus, discharge, and risk factors like diabetes mellitus, pregnancy, or immune suppression, and guide antifungal therapy decisions. Follow-up cytology or microbiology cultures may be used to determine species.

Imaging modality: Conventional cervical cytology (Pap smear) analyzed by light microscopy after Papanicolaou staining. Primary subject: an HSV-induced cytopathic change in cervical squamous epithelium, demonstrated as a multinucleated giant cell with characteristic intranuclear inclusions. Anatomical localization: cervix, transformation zone, squamous epithelium of the lower genital tract. Visual features: a large, rounded cell with abundant cytoplasm, multiple molded nuclei, marginated chromatin, and dense eosinophilic intranuclear inclusions (Cowdry type A). A perinuclear halo and nuclear molding are evident; nuclei tend to crowd together but do not fully overlap. Background typically contains neutrophils or inflammatory cells. Staining accentuates the eosinophilic nuclear inclusions and the halo, enabling recognition of HSV cytopathic effect. Pathological interpretation: cytopathic effects consistent with active herpes simplex virus infection of cervical epithelium (HSV cervicitis). Diagnostic significance: supports clinical suspicion of herpetic cervicitis; guides antiviral therapy and infection control; may prompt confirmatory testing (HSV PCR or viral culture). Differential considerations: cytomegalovirus infection (owl's eye inclusions) can mimic in some respects but shows solitary cells with distinct intranuclear inclusions; koilocytes from HPV are different. Clinical correlation: correlate with symptoms (dysuria, vaginal discharge, genital ulcers) and pregnancy status. Educational relevance: classic cytology example of HSV infection on Pap smear. Reproducible educational reference material.

Imaging modality: Conventional cervical cytology (Pap smear) analyzed by light microscopy after Papanicolaou staining. Primary subject: an HSV-induced cytopathic change in cervical squamous epithelium, demonstrated as a multinucleated giant cell with characteristic intranuclear inclusions. Anatomical localization: cervix, transformation zone, squamous epithelium of the lower genital tract. Visual features: a large, rounded cell with abundant cytoplasm, multiple molded nuclei, marginated chromatin, and dense eosinophilic intranuclear inclusions (Cowdry type A). A perinuclear halo and nuclear molding are evident; nuclei tend to crowd together but do not fully overlap. Background typically contains neutrophils or inflammatory cells. Staining accentuates the eosinophilic nuclear inclusions and the halo, enabling recognition of HSV cytopathic effect. Pathological interpretation: cytopathic effects consistent with active herpes simplex virus infection of cervical epithelium (HSV cervicitis). Diagnostic significance: supports clinical suspicion of herpetic cervicitis; guides antiviral therapy and infection control; may prompt confirmatory testing (HSV PCR or viral culture). Differential considerations: cytomegalovirus infection (owl's eye inclusions) can mimic in some respects but shows solitary cells with distinct intranuclear inclusions; koilocytes from HPV are different. Clinical correlation: correlate with symptoms (dysuria, vaginal discharge, genital ulcers) and pregnancy status. Educational relevance: classic cytology example of HSV infection on Pap smear. Reproducible educational reference material.

This medical image displays four panels (A, B, C, and D) illustrating Pap smear cytology samples from the Herlev database, used for medical machine learning research. The original clinical photograph (A) shows a single cervical cell with a distinct, darkly stained, round red nucleus and a surrounding lighter pink cytoplasm. Panels B, C, and D demonstrate various data augmentation techniques applied to the original image to improve neural network training. These include geometric transformations such as horizontal and vertical shifts, rotation, zooming, and shearing. There are also visible modifications in color saturation. These panels are used to teach computer vision models to recognize cellular features regardless of orientation or positioning, which is critical for the automated screening of cervical cancer and identifying dysplastic changes in columnar cells.

This medical image displays four panels (A, B, C, and D) illustrating Pap smear cytology samples from the Herlev database, used for medical machine learning research. The original clinical photograph (A) shows a single cervical cell with a distinct, darkly stained, round red nucleus and a surrounding lighter pink cytoplasm. Panels B, C, and D demonstrate various data augmentation techniques applied to the original image to improve neural network training. These include geometric transformations such as horizontal and vertical shifts, rotation, zooming, and shearing. There are also visible modifications in color saturation. These panels are used to teach computer vision models to recognize cellular features regardless of orientation or positioning, which is critical for the automated screening of cervical cancer and identifying dysplastic changes in columnar cells.

Reading File
Reading File
Searching PubMed

"cervical cancer screening" AND "Pap smear"

Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Now I have comprehensive information to provide a thorough answer. Let me compile everything.

Pap Smear (Papanicolaou Test)

Overview

The Pap smear is a cervical cancer screening test named after George Papanicolaou, who introduced the technique in the 1920s. It uses cells lightly scraped from the cervix - specifically from the transformation zone (TZ) at the squamocolumnar junction - to detect epithelial dysplasia before it becomes invasive cancer. Since its widespread introduction in the 1950s, cervical cancer deaths in the United States have declined by 70%, and the annual incidence dropped from 8 to 5 cases per 100,000 women. - Berek & Novak's Gynecology

Anatomy: The Transformation Zone

The transformation zone is the area most at risk in all age groups. Its location varies with age:
  • In younger women: the squamocolumnar junction (SCJ) is visible and the TZ can be large
  • With aging: the SCJ migrates inward into the canal
  • At menopause: the TZ is usually entirely within the canal and not visible
The entire TZ must be sampled to maximize efficacy of the Pap smear. - Pfenninger & Fowler's Procedures for Primary Care

Indications

  • Routine cervical cancer screening (per age-based guidelines)
  • Women on DES (diethylstilbestrol), immunocompromised, or HIV-positive patients
  • Abnormal vaginal bleeding or discharge
  • Visible/palpable cervical lesions (though Pap is not diagnostic - biopsy is needed)
  • Following hysterectomy for dysplasia/carcinoma: continue annually after 3-4 normal results
  • Victims of sexual assault (part of initial workup)
  • Investigation of atypical glandular/endometrial cells

Contraindications

  • Absolute: None
  • Relative: Active vaginitis/cervicitis, pelvic inflammatory disease, menstruation (defer routine screening; obtain regardless if patient has abnormal bleeding)

Screening Intervals (Current Guidelines)

PopulationRecommendation
Ages 21-29Cytology alone every 3 years
Ages 30-65Cytology + HPV co-testing every 5 years (preferred) OR cytology alone every 3 years
>65 with adequate prior screeningDiscontinue
Post-hysterectomy (benign)Discontinue
Post-hysterectomy (for dysplasia/carcinoma)Continue annually

Procedure Technique

Equipment needed: Lithotomy table, speculum (various sizes), Cytobrush/cervical broom/spatula, fixative or liquid-based transport vial.
Conventional slide method:
  1. Insert speculum without lubricant (lubricant can distort cells)
  2. Sample the endocervix with a Cytobrush (rotate 90-180 degrees, one direction only)
  3. Sample the ectocervix with a wooden/plastic spatula
  4. Spread spatula sample on slide first, then "unroll" the brush sample directly over it
  5. Immediately fix the slide with cytologic fixative
Liquid-based methods (ThinPrep / SurePath):
  • Use a cervical broom; rotate five full turns
  • Swish device in transport fluid at least 20 times (ThinPrep) OR pop broom head off into vial (SurePath)
  • Allows simultaneous HPV DNA reflex testing
In pregnancy:
  • Perform early in first trimester; the active TZ externalizes, so deep canal sampling is unnecessary
  • Prefer broom or spatula over wire-tip brushes (reduces bleeding risk)

Bethesda Classification System (2001)

Results are reported using the Bethesda System, developed at NCI in 1988 and updated in 2001:

Squamous Cell Abnormalities

Bethesda TermHistologic Correlation
ASC-USAtypical squamous cells of undetermined significance
ASC-HAtypical squamous cells, cannot exclude HSIL
LSILLow-grade SIL = CIN 1 + HPV koilocytotic changes
HSILHigh-grade SIL = CIN 2 and CIN 3 (moderate/severe dysplasia, CIS)
Squamous cell carcinomaInvasive cancer

Glandular Cell Abnormalities

  • AGC (atypical glandular cells) - endocervical, endometrial, or NOS
  • Endocervical adenocarcinoma in situ
  • Adenocarcinoma

Key Merges in Bethesda Logic

  • HPV changes + CIN 1 are combined into LSIL (same natural history, same distribution of HPV types)
  • CIN 2 + CIN 3 are combined into HSIL (similar biologic profile; management is the same)

Management of Abnormal Results

ResultManagement
ASC-USReflex HPV DNA testing (preferred); if high-risk HPV+ → colposcopy. OR repeat cytology at 6-month intervals × 2
ASC-HColposcopy
LSILColposcopy (may observe in adolescents - often self-limited)
HSILColposcopy + directed biopsy
AGCColposcopy; consider endometrial sampling (especially in women >40)
Absence of high-risk HPV has a negative predictive value of ≥98% for high-grade lesions. - Swanson's Family Medicine Review

Accuracy and Limitations

  • Sensitivity for detecting CIN 2/3: 47-62%; specificity: 60-95%
  • False-negative rate for a single conventional Pap smear: 20-50% (includes ThinPrep)
  • Major error sources: sampling error, poor fixation, laboratory interpretation errors, failure to follow up
  • More than half of invasive cancers occur in women who were never screened or underscreened
Liquid-based cytology (ThinPrep, SurePath) reduces sampling and preparation errors and enables automated computer-assisted screening. - Pfenninger & Fowler's Procedures for Primary Care

HPV & Cervical Cancer Connection

HPV infection - particularly high-risk types (HPV 16, 18) - is a necessary precursor for cervical carcinoma. Key facts:
  • 90% of HPV infections resolve spontaneously within 2 years
  • The remaining 10% of persistent infections can progress to precancerous lesions
  • HPV 16 carries the greatest risk of progression
  • Risk factors for progression: smoking, immunocompromise, early age of first intercourse, multiple sexual partners

Cytopathologic Findings on Pap Smear

Key microscopic changes seen on Pap staining:
Koilocytosis (HPV effect): enlarged, irregular, hyperchromatic nuclei with coarse chromatin, distinct perinuclear halo, cytoplasmic clearing - hallmark of LSIL
Cervical Pap smear showing HPV koilocytosis (left) vs. normal squamous cells (right)
HSV cervicitis: Multinucleated giant cells with intranuclear inclusions (Cowdry type A), nuclear molding, perinuclear halo
Pap smear showing HSV cytopathic effect - multinucleated giant cells with intranuclear inclusions
Candida: Budding yeast + pseudohyphae on inflammatory background

Common Procedural Errors to Avoid

  • Not sampling the entire transformation zone
  • Using lubricant on the speculum (distorts cellular morphology)
  • Air-drying the slide before fixation (causes artifacts)
  • Rotating Cytobrush more than 180 degrees
  • Not labeling specimens before collection
  • Failing to document whether an endocervical component was obtained

Recent Literature Note: A 2025 systematic review on barriers to Pap smear uptake in Asia (PMID: 40426094) and review of barriers in young women (PMID: 40080394) highlight that access, awareness, and cultural factors remain major obstacles globally. AI-assisted cytopathology is an active area per a 2024 systematic review (PMID: 39558397), with promising accuracy for automated cell classification.

Classify breast cancer

Reading File
Finding Sources
Finding Sources
Searching Images

breast cancer classification molecular subtypes histology

This educational diagram illustrates the intrinsic molecular subtypes of breast cancer categorized by their hormone receptor and HER2 status. At the top, a sagittal anatomical schematic of the breast shows a localized mass, which leads to a central node representing tumor classification. From this node, five distinct pathways branch to define specific subtypes: 1) Luminal A (HR+, ER+ and/or PR+, HER2-); 2) Luminal B (HR+, ER+ and/or PR+, HER2+/-); 3) Normal-like (HR+, ER+ and/or PR+, HER2-); 4) HER2-enriched (HER2+); and 5) Triple negative (HR-, ER-, PR-, HER2-). A legend defines the abbreviations used: HR (Hormone Receptor), ER (Estrogen Receptor), PR (Progesterone Receptor), and HER2 (Human Epidermal Growth Factor Receptor 2). This infographic is designed for medical education, aiding in the understanding of oncology classification, prognostic factors, and the immunohistochemical markers that guide clinical management in breast pathology.

This educational diagram illustrates the intrinsic molecular subtypes of breast cancer categorized by their hormone receptor and HER2 status. At the top, a sagittal anatomical schematic of the breast shows a localized mass, which leads to a central node representing tumor classification. From this node, five distinct pathways branch to define specific subtypes: 1) Luminal A (HR+, ER+ and/or PR+, HER2-); 2) Luminal B (HR+, ER+ and/or PR+, HER2+/-); 3) Normal-like (HR+, ER+ and/or PR+, HER2-); 4) HER2-enriched (HER2+); and 5) Triple negative (HR-, ER-, PR-, HER2-). A legend defines the abbreviations used: HR (Hormone Receptor), ER (Estrogen Receptor), PR (Progesterone Receptor), and HER2 (Human Epidermal Growth Factor Receptor 2). This infographic is designed for medical education, aiding in the understanding of oncology classification, prognostic factors, and the immunohistochemical markers that guide clinical management in breast pathology.

This diagnostic comparison chart displays MALDI-TOF mass spectrometry average spectra for breast cancer classification. The figure contains four subplots (A-D) showing 'Absolute Intensity' on the y-axis against 'm/z' (mass-to-charge ratio) on the x-axis, ranging from 700 to 3150. Subplot (A) compares Estrogen Receptor (ER) positive (green) and negative (orange) samples; (B) compares Progesterone Receptor (PR) positive (green) and negative (orange); (C) shows HER2 positive (green) and negative (orange); and (D) compares Triple-Negative Breast Cancer (TNBC) (green) and luminal subtypes (orange). Visually, the spectra are characterized by dense peptide peaks in the lower m/z range (700-1750), with intensity diminishing at higher mass ranges. Notable differential peak intensities are observed in the ER-positive and luminal groups compared to their counterparts, particularly around 1050 m/z. This educational material demonstrates the use of molecular profiling to identify distinctive peptide signatures associated with breast cancer receptor status and molecular subtypes.

This diagnostic comparison chart displays MALDI-TOF mass spectrometry average spectra for breast cancer classification. The figure contains four subplots (A-D) showing 'Absolute Intensity' on the y-axis against 'm/z' (mass-to-charge ratio) on the x-axis, ranging from 700 to 3150. Subplot (A) compares Estrogen Receptor (ER) positive (green) and negative (orange) samples; (B) compares Progesterone Receptor (PR) positive (green) and negative (orange); (C) shows HER2 positive (green) and negative (orange); and (D) compares Triple-Negative Breast Cancer (TNBC) (green) and luminal subtypes (orange). Visually, the spectra are characterized by dense peptide peaks in the lower m/z range (700-1750), with intensity diminishing at higher mass ranges. Notable differential peak intensities are observed in the ER-positive and luminal groups compared to their counterparts, particularly around 1050 m/z. This educational material demonstrates the use of molecular profiling to identify distinctive peptide signatures associated with breast cancer receptor status and molecular subtypes.

This medical infographic illustrates the complex landscape of biomarkers and cellular components involved in breast cancer diagnosis, classification, and the tumor microenvironment (TME). The diagram is divided into three functional sections. The 'Diagnostic and Classification' area lists critical tumor markers including EpCAM, HER2, ER, PR, Ki67, and PD-L1. The 'Molecular Subtypes' section provides specific biomarker profiles for Luminal A, Luminal B, HER2 Positive, and Triple Negative breast cancers, detailing the expression status of ER, PR, Her2, Ki67, EGFR, and CK. The 'Tumor Microenvironment' section displays various infiltrating immune cells and their associated surface markers: Regulatory T cells (Treg: TCR, PD-1, TIM-3), Natural Killer cells (NK: TIM-2, LAG3, TIGIT), B Cells (CD19, CD20), Cytotoxic T Lymphocytes (CTL: FAS, PD-1), Dendritic Cells (DC: CD80/86, MHC), Myeloid-Derived Suppressor Cells (MDSC: PD-L1, TGF-β), and Macrophages (MP: CD163, CD206, VEGF). This visual summary highlights the integrated approach needed for personalized oncology and immunotherapy selection.

This medical infographic illustrates the complex landscape of biomarkers and cellular components involved in breast cancer diagnosis, classification, and the tumor microenvironment (TME). The diagram is divided into three functional sections. The 'Diagnostic and Classification' area lists critical tumor markers including EpCAM, HER2, ER, PR, Ki67, and PD-L1. The 'Molecular Subtypes' section provides specific biomarker profiles for Luminal A, Luminal B, HER2 Positive, and Triple Negative breast cancers, detailing the expression status of ER, PR, Her2, Ki67, EGFR, and CK. The 'Tumor Microenvironment' section displays various infiltrating immune cells and their associated surface markers: Regulatory T cells (Treg: TCR, PD-1, TIM-3), Natural Killer cells (NK: TIM-2, LAG3, TIGIT), B Cells (CD19, CD20), Cytotoxic T Lymphocytes (CTL: FAS, PD-1), Dendritic Cells (DC: CD80/86, MHC), Myeloid-Derived Suppressor Cells (MDSC: PD-L1, TGF-β), and Macrophages (MP: CD163, CD206, VEGF). This visual summary highlights the integrated approach needed for personalized oncology and immunotherapy selection.

Educational medical graphic comparing breast cancer subtypes via a distribution chart and diagnostic ultrasound imaging. Panel (a) is a pie chart showing the prevalence of molecular subtypes: Luminal A (LA, 37.8%), Luminal B (LB, 36.8%), HER2-enriched (12.5%), and Triple-Negative (TN, 12.9%). Panels (b–e) present diagnostic ultrasound images illustrating characteristic features for each: (b) Luminal A (LA) subtype displaying a distinct hyperechoic halo and significant posterior acoustic shadowing; (c) Luminal B (LB) subtype demonstrated via color Doppler showing internal vascularity; (d) HER2-enriched subtype showing internal punctate calcifications and posterior acoustic enhancement; (e) Triple-Negative (TN) subtype presenting as an oval-shaped mass with a micro-lobulated margin. This comparison highlights how B-mode and Doppler ultrasound features such as margin morphology, echogenic boundary, and posterior acoustic phenomena vary across breast cancer molecular classifications, aiding in radiological-pathological correlation.

Educational medical graphic comparing breast cancer subtypes via a distribution chart and diagnostic ultrasound imaging. Panel (a) is a pie chart showing the prevalence of molecular subtypes: Luminal A (LA, 37.8%), Luminal B (LB, 36.8%), HER2-enriched (12.5%), and Triple-Negative (TN, 12.9%). Panels (b–e) present diagnostic ultrasound images illustrating characteristic features for each: (b) Luminal A (LA) subtype displaying a distinct hyperechoic halo and significant posterior acoustic shadowing; (c) Luminal B (LB) subtype demonstrated via color Doppler showing internal vascularity; (d) HER2-enriched subtype showing internal punctate calcifications and posterior acoustic enhancement; (e) Triple-Negative (TN) subtype presenting as an oval-shaped mass with a micro-lobulated margin. This comparison highlights how B-mode and Doppler ultrasound features such as margin morphology, echogenic boundary, and posterior acoustic phenomena vary across breast cancer molecular classifications, aiding in radiological-pathological correlation.

Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Searching PubMed

"breast cancer" AND "molecular subtypes" AND classification

Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full classification.

Classification of Breast Cancer

Breast cancer is a heterogeneous disease classified across four major axes: histological type, histological grade, molecular/receptor subtype, and anatomic/TNM stage. Each axis provides distinct clinical, prognostic, and therapeutic information.

1. Classification by Invasiveness

CategoryPercentageTypes
Non-invasive (In Situ)15-20%DCIS, LCIS
Invasive80-85%Multiple histological subtypes

Non-Invasive Breast Cancer

Ductal Carcinoma In Situ (DCIS)
  • Malignant cells confined within the ductal membrane
  • DCIS architectural patterns: papillary, cribriform, solid, comedo
  • Papillary/cribriform = lower grade, slower progression to invasion
  • Solid/comedo = higher grade; central necrosis → calcification (visible on mammography as pleomorphic/linear microcalcifications)
  • Grade and ER status are more prognostically important than architectural pattern
Lobular Carcinoma In Situ (LCIS)
  • No longer classified as Tis in AJCC 8th edition - now considered a benign/high-risk entity
  • Marker of elevated bilateral breast cancer risk

2. Histological Classification of Invasive Cancer

(Sabiston Textbook of Surgery)

No Special Type (NST) / Ductal NST - 50-70%

  • Most common type; no distinct architectural pattern
  • Gross: hard, irregular, radiodense mass with desmoplastic reaction
  • Classic "medullary pattern" (high-grade, TIL-rich) is now classified as invasive carcinoma NST with medullary pattern

Special Types

Histological TypeFrequencyKey Features
Invasive lobular5-15%Single-file ("Indian file") infiltration; E-cadherin loss; bilateral tendency
Tubular2-3%Well-formed tubules; excellent prognosis; low grade; ER+
Mucinous (colloid)2-3%Tumor cells floating in extracellular mucin; favorable prognosis
Invasive cribriform1-3%Cribriform glandular pattern; low-grade; good prognosis
Invasive papillary1-2%Papillary structures; older women; favorable
Adenoid cystic~1%Biphasic morphology; rarely metastasizes to lymph nodes
Metaplastic~1%High-grade, ER/PR/HER2 negative; node-negative but poor prognosis

Mixed Connective and Epithelial Tumors

  • Phyllodes tumors (benign and malignant) - <1%
  • Carcinosarcoma - <1%
  • Angiosarcoma - <1%

3. Histological Grading (Nottingham Grade)

All invasive carcinomas are graded using the Nottingham Histologic Score (Modified Scarff-Bloom-Richardson) based on three parameters, each scored 1-3:
ParameterScore 1Score 2Score 3
Tubule formation>75%10-75%<10%
Nuclear pleomorphismSmall, uniformModerate variationMarked variation
Mitotic rateLowModerateHigh
Total score:
  • Grade 1 (3-5): Well differentiated - tubular/cribriform pattern, small uniform nuclei, low proliferation
  • Grade 2 (6-7): Moderately differentiated - mixed tubular/solid, moderate pleomorphism
  • Grade 3 (8-9): Poorly differentiated - ragged sheets, enlarged irregular nuclei, necrosis, high mitotic rate
Invasive breast carcinoma grading - Grade 1, 2, and 3 histology
(Robbins, Cotran & Kumar Pathologic Basis of Disease)

4. Molecular / Receptor-Based Classification

Introduced by Perou et al. in 2000. Based on gene expression profiling, refined by IHC for clinical use.

The Five Intrinsic Subtypes (IHC Approximation)

Intrinsic SubtypeIHC ProfileClinical ClassPrognosis
Luminal AER+, PR+, HER2−, Ki-67 <14%HR-positiveBest overall survival
Luminal B (HER2−)ER+, PR low/−, HER2−, Ki-67 ≥14%HR-positiveWorse than Luminal A
Luminal B (HER2+)ER+, PR low/−, HER2+HR+/HER2+Intermediate
HER2-enrichedER−, PR−, HER2+HER2-positivePoor (pre-targeted therapy); improved with anti-HER2 agents
Basal-likeER−, PR−, HER2−Triple-negative (TNBC)Worst; highest metastatic risk
Normal-likeER+, PR+, HER2−HR-positiveSimilar to Luminal A
Claudin-lowER−, PR−, HER2−, low claudin expressionTNBC-likePoor; stem-cell features
Intrinsic molecular subtypes of breast cancer diagram

Clinical Groupings (Simplified)

Clinical GroupPrevalenceDefining Feature
Luminal (ER+/HER2−)~70%Hormone receptor-driven; tamoxifen/aromatase inhibitor responsive
HER2-positive~15%HER2 amplification; trastuzumab, pertuzumab, T-DM1 responsive
Triple-Negative (TNBC)~15%ER−/PR−/HER2−; chemotherapy ± immunotherapy (pembrolizumab)
Key biomarkers used clinically:
  • ER/PR: IHC; positive if ≥1% of cells stain (Allred score 0-8)
  • HER2: IHC scored 0/1+/2+/3+; 3+ = positive; 2+ = equivocal → confirm with FISH/CISH (HER2/CEP17 ratio ≥2.0 = amplified)
  • Ki-67: Proliferation marker; <10% = low, 10-20% = borderline, >20% = high
  • HER2-low (IHC 1+ or 2+ without amplification): emerging subgroup responsive to trastuzumab deruxtecan (T-DXd)
(Current Surgical Therapy 14e; Fischer's Mastery of Surgery 8e)

5. Anatomic Staging - AJCC 8th Edition TNM

(Mulholland & Greenfield's Surgery)

T - Primary Tumor

StageDescription
TisIn situ (DCIS only; LCIS excluded)
T1≤20 mm
- T1mi≤1 mm (microinvasion)
- T1a>1 mm to ≤5 mm
- T1b>5 mm to ≤10 mm
- T1c>10 mm to ≤20 mm
T2>20 mm to ≤50 mm
T3>50 mm
T4Any size, extends to chest wall/skin
- T4dInflammatory breast cancer (IBC) - ≥1/3 of skin involved

N - Regional Lymph Nodes

StageDescription
cN0/pN0No lymph node metastases
pN1miMicrometastases >0.2 mm but ≤2.0 mm, or >200 cells
cN1/pN11-3 ipsilateral mobile axillary nodes
cN2Fixed/matted axillary nodes
cN3Infraclavicular, internal mammary + axillary, or supraclavicular nodes

M - Distant Metastasis

StageDescription
M0No distant metastasis
M1Distant metastasis (bone, liver, lung, brain most common)

Anatomic Stage Groups

StageTNM
0TisN0M0
IT1N0M0
IIAT0-1N1M0; or T2 N0 M0
IIBT2N1M0; or T3 N0 M0
IIIAT0-3N2M0; or T3 N1 M0
IIIBT4N0-2M0
IIICAny TN3M0
IVAny TAny NM1
AJCC 8th Edition update: Now integrates pathologic prognostic staging - incorporates tumor grade, ER/PR/HER2 status alongside anatomic TNM, making it the first breast cancer staging system to include non-anatomic factors.

6. Special Biological Categories

Inflammatory Breast Cancer (IBC)

  • Rapid onset erythema, edema, peau d'orange of ≥1/3 of breast skin
  • Classified T4d regardless of tumor size
  • Most aggressive clinical presentation; typically ER−, high-grade

Hereditary Breast Cancer

  • BRCA1 mutations: Chr 17q21; associated with TNBC/basal-like phenotype; also ovarian CA
  • BRCA2 mutations: Chr 13q12.3; associated with luminal-type; also male breast CA, pancreatic, prostate CA
  • BRCA1/2 account for 80-90% of single-gene familial breast cancers and 3-6% of all breast cancers
  • BRCA1/2 carriers eligible for PARP inhibitors (olaparib, talazoparib)

7. Breast Cancer Evolution Pathways

Two major pathways by histological grade:
Model of breast cancer evolution - low-grade and high-grade pathways
  • Low-grade pathway: Almost always ER+/HER2− (Luminal A); evolves through flat epithelial atypia → atypical hyperplasia → low-grade DCIS → invasive carcinoma
  • High-grade pathway: More complex; produces Luminal B, HER2-enriched, or TNBC; greater genomic instability, frequent TP53 mutations, HER2 amplification, BRCA1/2 deficiency
(Robbins, Cotran & Kumar Pathologic Basis of Disease)

Summary Comparison of Molecular Subtypes

FeatureLuminal ALuminal BHER2-enrichedTNBC
Prevalence~38%~37%~13%~13%
ER/PR+/++/+/−−/−−/−
HER2−/++
Ki-67LowHighHighHigh
Grade1-22-333
PrognosisBestIntermediatePoor → improvedWorst
Primary RxEndocrineEndocrine ± chemoAnti-HER2 + chemoChemo ± immunotherapy
This is a shared conversation. Sign in to Orris to start your own chat.